Patents by Inventor Ping-Fu Cheng
Ping-Fu Cheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11613755Abstract: A nucleic acid-drug complex is provided in the present disclosure, which includes a nucleic acid sequence of an anti-PD-L1 aptamer and a CpG oligonucleotide sequence capable of activating TLR9, in which the CpG oligonucleotide sequence consists of a first fragment and a second fragment, and the nucleic acid sequence of the anti-PD-L1 aptamer is inserted between the first fragment and the second fragment.Type: GrantFiled: December 23, 2020Date of Patent: March 28, 2023Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Ping-Fu Cheng, Ya-Ling Chiu, Kang-Li Wang, Po-Yen Lin, Shih-Ta Chen, Tseng-Huang Liu, Pei-Shin Jiang
-
Publication number: 20210230600Abstract: A nucleic acid-drug complex is provided in the present disclosure, which includes a nucleic acid sequence of an anti-PD-L1 aptamer and a CpG oligonucleotide sequence capable of activating TLR9, in which the CpG oligonucleotide sequence consists of a first fragment and a second fragment, and the nucleic acid sequence of the anti-PD-L1 aptamer is inserted between the first fragment and the second fragment.Type: ApplicationFiled: December 23, 2020Publication date: July 29, 2021Applicant: Industrial Technology Research InstituteInventors: Ping-Fu CHENG, Ya-Ling CHIU, Kang-Li WANG, Po-Yen LIN, Shih-Ta CHEN, Tseng-Huang LIU, Pei-Shin JIANG
-
Patent number: 10864279Abstract: A linker-drug represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), C is a conjugator, L is a linker unit, D is a toxin unit, and n is an integer ranging from 1 to 4. The structure of the conjugator is represented by formula (II). In formula (II), X is a leaving group, each of R1 and R2 is independently a single bond or —NH—, and Z is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or a combination thereof. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. An antibody-drug conjugate (ADC) employing the above linker-drug is also provided.Type: GrantFiled: December 4, 2017Date of Patent: December 15, 2020Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Maggie Lu, May-Hua Chang, Jenn-Tsang Hwang, Ping-Fu Cheng, Li-Wen Chang, Yi-Ju Ko, Chi-Y Hung, Chun-Min Liu, Chia-Yu Fan
-
Patent number: 10618935Abstract: An antibody-drug conjugate (ADC) of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), p is an integer ranging from 1 to 26, A is an antibody, and -(L-D) is a linker-drug unit. L is a linker unit having a glycopeptide, and D is a drug unit. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. A method for forming an antibody-drug conjugate (ADC) is also provided.Type: GrantFiled: November 2, 2016Date of Patent: April 14, 2020Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Yi-Ju Ko, Jheng-Sian Li, Maggie Lu, On Lee, Ping-Fu Cheng, Chun-Min Liu
-
Patent number: 10101340Abstract: Described is a method of detecting a protein fragment in a urine sample and a serum sample. The protein fragment is a urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, or serum osteopontin fragment. The urine sample and the serum sample are obtained from the same individual.Type: GrantFiled: May 24, 2013Date of Patent: October 16, 2018Assignee: Bio Preventive Medicine Corp.Inventors: Wei-Ya Lin, Mary Ya-Ping Yeh, Tzu-Ling Tseng, Ping-Fu Cheng, Tsai-Wei Hsu, Hung-Yi Li, Yi-Ting Chen, Yuh-Feng Ling, Jin-Shuen Chen, Yen-Peng Li
-
Publication number: 20180169262Abstract: A linker-drug represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), C is a conjugator, L is a linker unit, D is a toxin unit, and n is an integer ranging from 1 to 4. The structure of the conjugator is represented by formula (II). In formula (II), X is a leaving group, each of R1 and R2 is independently a single bond or —NH—, and Z is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or a combination thereof. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. An antibody-drug conjugate (ADC) employing the above linker-drug is also provided.Type: ApplicationFiled: December 4, 2017Publication date: June 21, 2018Applicant: Industrial Technology Research InstituteInventors: Maggie Lu, May-Hua Chang, Jenn-Tsang Hwang, Ping-Fu Cheng, Li-Wen Chang, Yi-Ju Ko, Chi-Y Hung, Chun-Min Liu, Chia-Yu Fan
-
Patent number: 9983216Abstract: Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and ?-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing and staging liver fibrosis.Type: GrantFiled: September 15, 2017Date of Patent: May 29, 2018Assignee: Industrial Technology Research InstituteInventors: Tzu-Ling Tseng, Hung-Yi Li, Yen-Peng Li, Angelina Huai-Lo Lee, Yi-Chen Liu, Ping-Fu Cheng, Wei-Ya Lin, Hong-Zen Yeh
-
Publication number: 20180003722Abstract: Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and ?-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing and staging liver fibrosis.Type: ApplicationFiled: September 15, 2017Publication date: January 4, 2018Inventors: Tzu-Ling Tseng, Hung-Yi Li, Yen-Peng Li, Angelina Huai-Lo Lee, Yi-Chen Liu, Ping-Fu Cheng, Wei-Ya Lin, Hong-Zen Yeh
-
Patent number: 9791460Abstract: Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and ?-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis.Type: GrantFiled: December 13, 2013Date of Patent: October 17, 2017Assignee: Industrial Technology Research InstituteInventors: Tzu-Ling Tseng, Hung-Yi Li, Yen-Peng Li, Angelina Huai-Lo Lee, Yi-Chen Liu, Ping-Fu Cheng, Wei-Ya Lin, Hong-Zen Yeh
-
Publication number: 20170119902Abstract: An antibody-drug conjugate (ADC) of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), p is an integer ranging from 1 to 26, A is an antibody, and -(L-D) is a linker-drug unit. L is a linker unit having a glycopeptide, and D is a drug unit. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. A method for forming an antibody-drug conjugate (ADC) is also provided.Type: ApplicationFiled: November 2, 2016Publication date: May 4, 2017Applicant: Industrial Technology Research InstituteInventors: Yi-Ju KO, Jheng-Sian LI, Maggie LU, On LEE, Ping-Fu CHENG, Chun-Min LIU
-
Publication number: 20140106370Abstract: Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and ?-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis.Type: ApplicationFiled: December 13, 2013Publication date: April 17, 2014Applicant: Industrial Technology Research InstituteInventors: Tzu-Ling Tseng, Hong-Yi Li, Ye-Peng Li, Angelina Huai-Lo Lee, Yi-Chen Liu, Ping-Fu Cheng, Wei-Ya Lin, Hong-Zen Yeh
-
Publication number: 20130252267Abstract: Described are uses of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.Type: ApplicationFiled: May 24, 2013Publication date: September 26, 2013Inventors: Wei-Ya Lin, Mary Ya-Ping Yeh, Tzu-Ling Tseng, Ping-Fu Cheng, Tsai-Wei Hsu, Hung-Yi Li, Yi-Ting Chen, Yuh-Feng Ling, Jin-Shuen Chen, Yen-Peng Li
-
Patent number: 8476077Abstract: Disclosed is use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.Type: GrantFiled: December 15, 2010Date of Patent: July 2, 2013Assignee: Industrial Technology Research InstituteInventors: Wei-Ya Lin, Mary Ya-Ping Yeh, Tzu-Ling Tseng, Ping-Fu Cheng, Tsai-Wei Hsu, Hung-Yi Li, Yi-Ting Chen, Yuh-Feng Ling, Jin-Shuen Chen, Yen-Peng Li
-
Patent number: 8465980Abstract: Disclosed is use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.Type: GrantFiled: January 27, 2010Date of Patent: June 18, 2013Assignee: Industrial Technology Research InstituteInventors: Wei-Ya Lin, Mary Ya-Ping Yeh, Tzu-Ling Tseng, Ping-Fu Cheng, Tsai-Wei Hsu, Hung-Yi Li, Yi-Ting Chen, Yuh-Feng Ling, Jin-Shuen Chen, Yen-Peng Li
-
Patent number: 8076089Abstract: Biomarkers for liver diseases and method for using the same are provided. For detecting liver cirrhosis and liver cancer, the biomarkers are selected from any one of the amino acid sequences with SEQ ID NO:1 to SEQ ID NO:24 or derivatives or fragments or variants or the combination thereof or the antibodies against the amino acid sequences. Then the biomarkers are further developed into detection kits, such that by detecting the existence of autoantibodies or autoantigens in screened specimens, liver diseases are detected with higher accuracy and sensitivity.Type: GrantFiled: April 20, 2010Date of Patent: December 13, 2011Assignee: Industrial Technology Research InstituteInventors: Tzu Ling Tseng, Ping Fu Cheng
-
Patent number: 7986368Abstract: A digital photo frame with photographing function includes a digital frame, a lens module, a bracket, and a copy stand. The digital frame may further include a display module, a frame, a memory module, a control module, an input module, a power supply module, and a sense module. The display module is framed within the frame, and the lens module is disposed at a predetermined location on the frame. A paper photo can be disposed on the copy stand that is pivotally connected to the bracket. The input module can input a control signal to operate and control the lens module to copy photograph the paper photo into a digital photo and store the digital photo in the memory module and further display the digital photo on the display module.Type: GrantFiled: November 14, 2007Date of Patent: July 26, 2011Assignee: Aiptek International IncInventors: Lien-Chen Lin, Ping-Fu Cheng, Chen-Loon Chang
-
Publication number: 20110086371Abstract: Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.Type: ApplicationFiled: December 20, 2010Publication date: April 14, 2011Applicant: Industrial Technology Research Institute(ITRI)Inventors: Wei-Ya Lin, Mary Ya-Ping Yeh, Tzu-Ling Tseng, Ping-Fu Cheng, Tsai-Wei Hsu, Hung-Yi Li, Yi-Ting Chen, Yuh-Feng Ling, Jin-Shuen Chen, Yen-Peng Li
-
Publication number: 20110079077Abstract: Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.Type: ApplicationFiled: December 15, 2010Publication date: April 7, 2011Applicant: Industrial Technology Research Institute(ITRI)Inventors: Wei-Ya Lin, Mary Ya-Ping Yeh, Tzu-Ling Tseng, Ping-Fu Cheng, Tsai-Wei Hsu, Hung-Yi Li, Yi-Ting Chen, Yuh-Feng Ling, Jin-Shuen Chen, Yen-Peng Li
-
Publication number: 20100261209Abstract: Biomarkers for liver diseases and method for using the same are provided. For detecting liver cirrhosis and liver cancer, the biomarkers are selected from any one of the amino acid sequences with SEQ ID NO:1 to SEQ ID NO:24 or derivatives or fragments or variants or the combination thereof or the antibodies against the amino acid sequences. Then the biomarkers are further developed into detection kits, such that by detecting the existence of autoantibodies or autoantigens in screened specimens, liver diseases are detected with higher accuracy and sensitivity.Type: ApplicationFiled: April 20, 2010Publication date: October 14, 2010Applicant: Industrial Technology Research InstituteInventors: Tzu-Ling TSENG, Ping-Fu Cheng
-
Patent number: 7807378Abstract: The present invention relates to methods of diagnosing myasthenia gravis in a subject, by determining an amount of at least one autoantibody that specifically binds one or more autoantigens selected from heat-shock protein 60 (hsp60), heat-shock protein 90, alpha isoform (hsp90?), and heat-shock protein 90, beta isoform (hsp90?). The invention also provides diagnostic kits for identifying a subject having myasthenia gravis.Type: GrantFiled: December 29, 2005Date of Patent: October 5, 2010Assignees: Industrial Technology Research Institute (ITRI), National Health Research Institutes (NHRI), Shin Kong Wu Ho-Su Memorial HospitalInventors: Tzu-Ling Tseng, Pei-Hsiu Liao, Ping-Fu Cheng, Shih-Feng Tsai, Hou-Chang Chiu